Literature DB >> 23449980

Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).

Kwang H Ahn1, Mariam M Mahmoud, Joong-Youn Shim, Debra A Kendall.   

Abstract

The cannabinoid receptor 1 (CB1) is a G protein-coupled receptor primarily expressed in brain tissue that has been implicated in several disease states. CB1 allosteric compounds, such as ORG27569, offer enormous potential as drugs over orthosteric ligands, but their mechanistic, structural, and downstream effects upon receptor binding have not been established. Previously, we showed that ORG27569 enhances agonist binding affinity to CB1 but inhibits G protein-dependent agonist signaling efficacy in HEK293 cells and rat brain expressing the CB1 receptor (Ahn, K. H., Mahmoud, M. M., and Kendall, D. A. (2012) J. Biol. Chem. 287, 12070-12082). Here, we identify the mediators of CB1 receptor internalization and ORG27569-induced G protein-independent signaling. Using siRNA technology, we elucidate an ORG27569-induced signaling mechanism for CB1 wherein β-arrestin 1 mediates short term signaling to ERK1/2 with a peak at 5 min and other upstream kinase components including MEK1/2 and c-Src. Consistent with these findings, we demonstrate co-localization of CB1-GFP with red fluorescent protein-β-arrestin 1 upon ORG27569 treatment using confocal microscopy. In contrast, we show the critical role of β-arrestin 2 in CB1 receptor internalization upon treatment with CP55940 (agonist) or treatment with ORG27569. These results demonstrate for the first time the involvement of β-arrestin in CB1-biased signaling by a CB1 allosteric modulator and also define the differential role of the two β-arrestin isoforms in CB1 signaling and internalization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449980      PMCID: PMC3617280          DOI: 10.1074/jbc.M112.438804

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis.

Authors:  W E Miller; S Maudsley; S Ahn; K D Khan; L M Luttrell; R J Lefkowitz
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

2.  Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference.

Authors:  Seungkirl Ahn; Christopher D Nelson; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

3.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

Review 4.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

5.  The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex.

Authors:  K A DeFea; Z D Vaughn; E M O'Bryan; D Nishijima; O Déry; N W Bunnett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression.

Authors:  Reema Goel; Polly J Phillips-Mason; Daniel M Raben; Joseph J Baldassare
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

Review 7.  Cellular signal transduction by anandamide and 2-arachidonoylglycerol.

Authors:  A C Howlett; S Mukhopadhyay
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

8.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

9.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.

Authors:  L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

10.  Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol.

Authors:  Tony Warne; Patricia C Edwards; Andrew G W Leslie; Christopher G Tate
Journal:  Structure       Date:  2012-05-09       Impact factor: 5.006

View more
  62 in total

1.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

2.  Activation of GPR18 by cannabinoid compounds: a tale of biased agonism.

Authors:  Linda Console-Bram; Eugen Brailoiu; Gabriela Cristina Brailoiu; Haleli Sharir; Mary E Abood
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 3.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

4.  Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 5.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 6.  New Insights in Cannabinoid Receptor Structure and Signaling.

Authors:  Lingyan Ye; Zheng Cao; Weiwei Wang; Naiming Zhou
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

7.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

Review 8.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

Review 10.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.